|Articles|March 8, 2022
- Pharmaceutical Executive-03-01-2022
- Volume 42
- Issue 3
Pharmaceutical Executive, March 2022 Issue (PDF)
Advertisement
Articles in this issue
over 4 years ago
Pressed Into Action: Measuring Pharma’s Reputation Reversalover 4 years ago
Biopharma in 2021: Big Gains, Volatile Valuesover 4 years ago
The Resilience of R&D: Pharma Posted Record Output in 2021over 4 years ago
New Age of Psychedelicsover 4 years ago
Roads Less Traveledover 4 years ago
Biopharma Stocks, M&A Sputter Amid More Headwindsover 4 years ago
Pandemic Accelerates CTV Ascent: How Pharma Can Benefitover 4 years ago
The Human Factor in Data Security Breachesover 4 years ago
Tapping the Surge in Useful Contingent Labor MarketAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Artisan Partners’ Director Calls for Novartis Board Shake-Up
2
340B Under Pressure: Inside Pharma's Push for Greater Clarity
3
The Agentic AI Revolution in Biopharma
4
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
5
